Moderna’s Post

📣Swissmedic approves Beyfortus for RSV prophylaxis in newborns, infants and young children Following a thorough review, Swissmedic has authorised the medicinal product Beyfortus from marketing authorisation holder Sanofi-Aventis (Suisse) SA. Beyfortus is used for the prophylaxis of lower respiratory tract disease caused by the respiratory syncytial virus (RSV). RSV is a respiratory tract virus that usually causes mild, cold-like symptoms. In newborns, infants and young children, however, the virus can trigger illness leading to pneumonia or bronchiolitis (inflammation of the small airways in the lungs). Beyfortus (with the monoclonal antibody nirsevimab) is administered intramuscularly as a single injection.

The #viralrespiratoryinfectionstreatment market offers diverse solutions. Antiviral medications combat infections directly, while vaccines prevent viral spread. #Monoclonalantibodies target specific pathogens, bolstering the immune response. Non-steroidal anti-inflammatory drugs (NSAIDs) alleviate symptoms and inflammation. The market's comprehensive range addresses varied needs, emphasizing the importance of tailored approaches in treating viral respiratory infections for enhanced patient outcomes and public health. To know more about the study, visit: https://lnkd.in/dzXzYFYJ #DBMR #RespiratoryHealth #ViralInfections #AntiviralMedication #VaccineTherapy #MonoclonalAntibodies #NSAIDTreatment #InfectionPrevention #HealthcareInnovation #PatientCare #GlobalHealth #TreatmentOptions #MedicalResearch #PublicHealth #Pharmaceuticals #InfectiousDiseaseControl #DBMRInsights

In a world facing a "tripledemic" threat of COVID-19, RSV, and influenza, medical experts are racing against time to protect us. Aridis Pharmaceuticals (OTC: ARDS) is at the forefront of the battle, advancing monoclonal antibodies (mAbs) to fight life-threatening infections. Their cutting-edge technology leverages the human immune system to target infectious diseases, including COVID, offering a fresh approach in a world grappling with drug resistance and the shortcomings of current treatments. Learn more and read our disclosures - https://ow.ly/yVHg50PX8VM #AridisPharmaceuticals #InfectiousDisease #MonoclonalAntibodies #COVID19 #MedicalAdvancements #HealthcareHeroes #ARDS

This week’s e-newsletter, Spotlight on CITF-funded Research, features results from four CITF-funded studies plus the latest infection-acquired seroprevalence in Canada data. One of the studies, published in Nature Communications, found that Pfizer and Moderna bivalent vaccines induced similar neutralization against Omicron subvariants BA.1, BA.5, BQ.1.1, and XBB.1.5 in patients on dialysis or with a kidney transplant, despite being antigenically divergent from strains circulating at the time. Another CITF-funded study, published in PLOS One, found that COVID-19 was the primary cause of hospitalization for half of hospitalized patients who tested positive for SARS-CoV-2. Patients admitted for COVID-19 were more likely to require ICU admission and to die than patients admitted with incidental SARS-CoV-2 infection. Our Seroprevalence in Canada web page shows that infection-acquired seroprevalence in Canada was stable at the end of August. Also, new estimates from the CITF-funded EnCORE study, measuring seroprevalence in children and adolescents in the Montreal region, showed that overall infection-acquired seroprevalence in children (2-19) rose from 58.1% (end of September 2022) to 79.4% (end of June 2023). More: https://ow.ly/79aO50PYkBq

🌍💉 Join us for a webinar as we explore vaccine development—an essential pillar of public health against infectious diseases: https://buff.ly/46SaiZb Our experts will shed light on the critical need for an integrated approach between clinical and laboratory teams right from the early stages, well before protocol development. Discover how robust laboratory and IT capabilities, coupled with innovative automation, elevate the efficiency of vaccine development. #Vaccine #ClinicalResearch #CRO #VaccineDevelopment #VaccineClinicalTrials

Abstract: “We evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03–0.59 million) hospitalizations and save US $56.95 billion (95% CI US $2.62–$122.63 billion). In a higher transmission scenario (effective reproduction number of 3), the benefits increase, potentially preventing 0.85 million (95% CI 0.36–1.38 million) hospitalizations and saving US $170.17 billion (95% CI US $60.49–$286.14 billion). Our findings suggest that timely and widespread use of Paxlovid could be an effective and economical approach to mitigate the effects of COVID-19.”

💉 Understanding Respiratory Syncytial Virus (RSV): The Silent Threat to Infants and Adults Respiratory Syncytial Virus (RSV) often presents with mild, cold-like symptoms but can be severe in vulnerable groups such as infants and older adults. Recognizing the impact and symptoms of RSV is crucial for effective management. While RSV shares similarities with COVID-19, key differences in symptoms and severity can aid in accurate diagnosis and timely treatment. Notable progress has been made over the last few years in the RSV space with more exciting developments expected in the coming months. Are you interested in learning more about the market outlook and key players in RSV Vaccines? 👉 Stay tuned for more posts in the coming days. #RSV #respiratoryvaccines #healthcare #pharmaceuticals #biotech

The ivermectin story: that of a dead horse. One that never had any legs to stand on. The ivermectin reviews published in the American Journal of Therapeutics do not contain anything that should keep people from vaccination. The expressions of concern – both of which cite a paper in Nature Medicine by Jack M. Lawrence, Gideon Meyerowitz-Katz, James A. J. Heathers, Nicholas J. L. Brown, and Kyle A. Sheldrick detailing the issues with work on ivermectin – are nearly identical, save for a critical difference. The one for “Review of the Emerging Evidence,” by Kory and colleagues, reads: The decision is based on the evaluation of allegations of inaccurate data collection and/or reporting in at least one of the primary sources of the meta-analysis contained in the article. These allegations were first made after the publication of this article. The exclusion of the suspicious data appears to raise questions regarding ivermectin’s potential to decrease the mortality of COVID-19 infection. Currently, the investigation of these allegations is incomplete and inconclusive. https://lnkd.in/eDYEtZAu

Beyfortus Receives Approval in China for Infant Respiratory Syncytial Virus Disease Prevention AstraZeneca's nirsevimab, known as Beyfortus, has been approved in China to prevent lower respiratory tract infections caused by respiratory syncytial virus (RSV) in infants. The approval covers a wide range of infant populations and is based on evidence from clinical trials. RSV is a prevalent virus in China, and this approval is significant in preventing severe infections in infants. AstraZeneca is committed to addressing the needs of vulnerable populations and reducing the burden of infectious diseases. Beyfortus has already been approved in the EU and the US and is awaiting regulatory decisions in other countries. For more details please click the link! https://lnkd.in/d3MeZ7uw #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Superbugs threaten us all — it’s time for Congress to act Antibacterial-resistant infections contributed to nearly 5 million deaths worldwide in 2019. In the United States, superbugs were the third leading cause of death from disease in 2019, behind heart disease and cancer, linked to nearly 173,000 deaths. The global death toll from this public health crisis is set to top 10 million annually by 2050 — exceeding the number of people who die from cancer. We must act to combat superbugs — and fast. Thankfully, there’s a common-sense solution at hand. A bill known as the PASTEUR Act, which was recently reintroduced in Congress by a bipartisan group of lawmakers in both the House and the Senate, would jump-start the arsenal of new antimicrobial medicines we need to counteract the accelerating superbug pandemic. https://lnkd.in/eVQTjNPH Acurx Pharmaceuticals Inc is a publicly held, clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration. #acurx #nasdaq #acxp